This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Chilingirova N, Hammoudeh Z, Balabanski L, Ivanov S, Vazharova R, Nikolova D, et al. TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer. memo Magazine of European Medical Oncology. 2016; 9(1): 30-38 (https://link.springer.com/article/10.1007/) s12254-015-0244-2.ChilingirovaNHammoudehZBalabanskiLIvanovSVazharovaRNikolovaDTruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancermemo Magazine of European Medical Oncology20169130–38(https://link.springer.com/article/10.1007/s12254-015-0244-210.1007/s12254-015-0244-2Search in Google Scholar
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2): 71-96.JemalASiegelRWardEHaoYXuJMurrayTCancer statistics, 2008CA Cancer J Clin200858271–9610.3322/CA.2007.0010Search in Google Scholar
Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. Plos One. 2009; 4(2): e4576.GandhiJZhangJXieYSohJShigematsuHZhangWAlterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell linesPlos One200942e457610.1371/journal.pone.0004576Search in Google Scholar
Sadowska AM, Nowé V, Janssens A, Boeykens E, De Backer WA, Germonpré PR. Customizing systemic therapy in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol. 2011; 3(4): 207-218.SadowskaAMNowéVJanssensABoeykensEDeBacker WAGermonpréPRCustomizing systemic therapy in patients with advanced non-small cell lung cancerTher Adv Med Oncol201134207–21810.1177/1758834011409000Search in Google Scholar
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239-246.RosellRCarcerenyEGervaisRVergnenegreAMassutiBFelipEErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trialLancet Oncol2012133239–24610.1016/S1470-2045(11)70393-XSearch in Google Scholar
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21): 2129-2139.LynchTJBellDWSordellaRGurubhagavatulaSOkimotoRABranniganBWActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129–213910.1056/NEJMoa040938Search in Google Scholar
Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009; 28(Suppl 1): S24-S31.GazdarAFActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene200928Suppl 1S24–S3110.1038/onc.2009.198Search in Google Scholar
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al., EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101(36): 13306-13311.PaoWMillerVZakowskiMDohertyJPolitiKSarkariaIEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci USA20041013613306–1331110.1073/pnas.0405220101Search in Google Scholar
Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study. Lung Cancer. 2004; 44(2): 221-230.JännePAGurubhagavatulaSYeapBYLuccaJOstlerPSkarinATOutcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access studyLung Cancer2004442221–23010.1016/j.lungcan.2003.12.014Search in Google Scholar
Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: A meta-analysis. Lung Cancer. 2001; 31(2-3): 139-148.KhuderSAEffect of cigarette smoking on major histological types of lung cancer: A meta-analysisLung Cancer2001312-3139–14810.1016/S0169-5002(00)00181-1Search in Google Scholar
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3): 169-181.SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer200773169–18110.1038/nrc2088Search in Google Scholar
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25): 2380-2388.MaemondoMInoueAKobayashiKSugawaraSOizumiSIsobeHGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380–238810.1056/NEJMoa0909530Search in Google Scholar
Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, et al., Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 Trial. J Clin Oncol. 2012; 30(17): 2063-2069.JännePAWangXSocinskiMACrawfordJStinchcombeTEGuLRandomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 TrialJ Clin Oncol201230172063–206910.1200/JCO.2011.40.1315Search in Google Scholar
Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009; 10(5): 432-433.HirschFRBunnPA JrEGFR testing in lung cancer is ready for prime timeLancet Oncol2009105432–43310.1016/S1470-2045(09)70110-XSearch in Google Scholar
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676): 1497-1500.PaezJGJännePALeeJCTracySGreulichHGabrielSEGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapyScience200430456761497–150010.1126/science.1099314Search in Google Scholar
